Norgestrel + ethinylestradiol

Generic Medicine Info
Present or history of thromboembolic disorders, cerebral-vascular or coronary-artery disease; thrombogenic valvulopathies or rhythm disorders; surgery with prolonged immobilisation; diabetes with vascular involvement; headaches with focal neurological symptoms; uncontrolled hypertension; breast or endometrium cancer or other oestrogen dependent tumours; liver cancers or active liver disease; undiagnosed abnormal genital bleeding; jaundice or history of cholestatic jaundice of pregnancy. Pregnancy.
Special Precautions
Hypertension, hypercholesterolaemia, obesity, DM, surgery or trauma with thrombotic risk, conditions which may be worsened by fluid retention, renal disease, impaired liver function. History of depression. May worsen gallbladder disease. Increased risk of severe CV side effects with smoking. Discontinue if there is unexplained partial or loss of vision, significant increase in BP or persistent or severe headache. Lactation.
Adverse Reactions
GI disturbances, breakthrough bleeding (especially in 1st 3 mth of use), hypercholesterolaemia, hypertension, headache, oedema, mood changes, melasma.
Potentially Fatal: Increased risk of MI, venous thromboembolic and thrombotic disease, cerebrovascular events, vascular disease, ocular lesions (e.g. retinal thrombosis), breast, cervical and liver cancer.
Drug Interactions
Reduced contraceptive effectiveness with antibiotics, anticonvulsants and drugs that may increase contraceptive steroids clearance (e.g. bosentan, rifampicin, rifabutin, barbiturates, primidone, phenytoin, carbamazepine, oxcarbazepine, topiramate, griseofulvin, aprepitant). Severe pruritus and jaundice with troleandomycin, avoid concurrent use. Decreased effectiveness of ursodeoxycholic acid by increasing the elimination of cholesterol in bile. Effects of danazol or gestrinone and hormonal contraceptives might be altered or reduced by concurrent use, avoid concomittant use. Decreased contraceptive effectiveness with anti-HIV protease inhibitors. Increased tacrolimus levels with ethinyl estradiol. May increase theophylline, selegiline and tizanidine levels with oral contraceptives.
CIMS Class
Disclaimer: This information is independently developed by CIMS based on norgestrel + ethinylestradiol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in